Connect with us

Business

Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s Both Batches Of Clinical Trial Products Complete All The Ten Release Tests

Published

on

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is pleased to announce that both batches of its clinical trial products have passed all the ten release tests as mandated by the US FDA. The company will receive a certificate of analysis for each batch of the clinical trial product from its partner – Austrianova Singapore. It will also receive all the completed records that comprise data about the safety and functionality of encapsulated cells. The tests allow Pharmacyte to submit the required data to the US FDA and seek approval for the planned clinical trial in LAPC (Locally advanced inoperable pancreatic cancer).

Both batches of clinical trial products pass 20 tests

Kenneth L Waggoner, Chief Executive Officer of Pharmacyte, said the company is pleased to know that the capsules and the live cells inside are performing satisfactorily during the tests. The company can try these products inside the patients with LAPC in the upcoming clinical trial without any safety issues. Kenneth said both the batches of clinical trial products passed all the 20 tests. The company awaits the certificates of analysis along with records from Austrianova.

Completes seven of the ten release tests in December 2019

Pharmacyte previously announced in December 2019, that both batches of the clinical trial products passed seven of the ten tests required by the US FDA. Waggoner said the company is pleased that all the clinical trial products in each batch are performing during the release test very well. The 10 tests are conducted on Austrianove produced clinical trial products. It collects the essential data from these tests and other vital information to apply for investigational new drug application to the US FDA, which allows clinical trial in patients with LAPC.

Over 50,000 Americans are diagnosed with adenocarcinoma every year. Most of these people will die by the end of the first year. Pancreatic cancer is the 4th leading cause of the deaths in women and men. The survival rates have improved in the past 15 years, thanks to advanced research and development of cancer therapies. Around 15 to 20% of the people diagnosed with pancreatic cancer are the best candidates for surgery.

The clinical-stage biotechnology company Pharmacyte focuses on the development and commercialization of cellular therapies for diabetes and cancer in the US. The company develops cellular therapies using its proprietary cellulose-based live-cell encapsulation technology called Call-in-a-Box to treat diabetes and cancers that include locally advanced and inoperable pancreatic cancer (LAPC). The company changed its name to Pharmacyte in January 2015 from Nuvilex Inc.

Business

Acreage Holdings Inc (OTCMKTS:ACRGF) Inaugurates A Medical Dispensary – The Botanist In Spring Hill, Florida: Larissa Herda Resigns From The Board of Acreage

Published

on

Acreage Holdings Inc (OTCMKTS:ACRGF) inaugurated The Botanist in the Spring Hill, Florida. It is the first medical cannabis dispensary of Acreage in the state. The company now holds consulting and management services and other accords that include pending takeovers for thirty-two operational dispensaries in thirteen states that comprise fourteen The Botanist branded dispensaries. Acreage invests in cannabis industries.

The Botanist Brand

The Botanist Brand, which is developed by Acreage, is a product and retail brand with deep roots in wellness and health. It helps individuals to maintain healthy lifestyles using the holistic power of cannabis. The Botanist provides a wide gamut of products derived from cannabis. It also features a retail design – the science meets nature, which is reminiscent of the nineteenth-century botanist laboratory. The Botanist in the Spring Hill boasts its signature green foliage wall and a private consultation room and provides an environment for enthusiasts like you to know about the healing properties of cannabis plants from the trained specialists in patient-care.

Larissa Herda resigns from the board

According to a communiqué from Acreage, Larissa Herda has relinquished as a member of the board. Kevin Murphy, Chief Executive Officer and Chair of Acreage said the company conveyed thanks for her exceptional services all along its journey since joining the board in November 2018 and wished success in her future endeavors.

Closes previously announced credit facility

Acreage has successfully closed the previously announced credit facility of $100 million. It has drawn $21 million from this credit facility. The subsidiary of Acreage – IP Borrower has also borrowed $22 million from IP Investment Company LLC.

Acreage has agreed to make monthly payments at an annual interest of 3.55% on the first advance, 1.85% on the second advance, and 1.55% for the third advance for the first year. It will negotiate interest rates for the second year. IP Borrower provides a guarantee for the credit facility. It will also provide security of $22 million from the loan transaction. The amount of $22 million will be blocked in the account as a safety to the Institutional lender.

The Borrower needs to provide cash collateral to draw the balance amount of $78 million. However, the institutional lender will not hold any security in the subsidiaries of Acreage or Acreage.

Continue Reading

Business

TerrAscend Canada Inc, A Subsidiary Of Terrascend Corp (OTCMKTS:TRSSF), Enters A $80.5 Million CAD Loan Financing Accord With Canopy Growth Corp (NYSE:CGC)

Published

on

TerrAscend Canada Inc, a subsidiary of Canopy Rivers Inc (OTCMKTS:CNPOF), has entered into an $80.5 Million CAD loan financing agreement with Canopy Growth Corp (NYSE:CGC). As per the terms of the deal, Canopy Growth has received 17.8 million common shares purchase warrants from TerrAscend.

Well-positioned to capitalize on opportunities

CEO and President of Canopy Rivers, Narbe Alexandrian, said it shows the confidence in TerrAscend’s capability to implement the strategic mandate for domestic and international markets. He said the team at TerrAscend is well-positioned to leverage the flourishing opportunities in the regulated jurisdictions using its network and resources. Narbe is pleased with the support extended by Canopy Growth for its portfolio company – TerrAscend.

Proceeds for general corporate purposes

TerrAscend Canada will use the proceeds to fund the Canadian operations and for general corporate purposes. It will also use the funds to repay indebtedness and to support global expansion and its Arise Bioscience U.S. hemp division.

Receives a permit to cultivate medical marijuana

TerrAscend has announced the receipt of a permit from the New Jersey Department of Health to cultivate medical marijuana. Its subsidiary TerrAscend NJ will commence the cultivation immediately at its facility situated in Boonton Township, northern New Jersey. It is the second entity in New Jersey among the six applicants selected in December 2018 by the Department of Health. TerrAscend NJ can commence manufacturing after the receipt of dispensing and additional processing approvals. It can manage up to three dispensaries in the northern area of New Jersey.

66,000 patients’ gains access to the medical marijuana program

More than 66,000 patients have gained access to the medical marijuana program as of January 2020 in New Jersey. The registered medical patients’ count has almost tripled since early 2018.

TerrAscend has purchased a sixteen-acre site in Boonton Township. It commenced the construction on an area of 227,000 Sq. Ft. under the first phase to cover cultivation, support space, and processing on 80,000 Sq. Ft. The first phase will become operational in H1 2020.

TerrAscend will supply the wholesale customers and its dispensaries by sourcing the cannabis products from its scaled cultivation capacity. It also expects to meet the demand for fifteen new retail dispensaries using cannabis from the scaled cultivation facility.

Continue Reading

Business

Medipharm Labs Corp (OTCMKTS:MEDIF) Expects To Begin Supply Of Pharmaceutical-quality cannabis oil products in Australia

Published

on

Medipharm Labs Corp (OTCMKTS:MEDIF) will supply pharmaceutical quality cannabis oil products in Australia. It is on the backdrop of a two-year agreement signed between Compass Clinics Australia Pty Ltd and MediPharm Labs Australia Pty Ltd.

Provides education and consultation services

Compass Clinics provides education and consultation services to Australian patients who look to access medical cannabis products. The company inaugurated its first two clinics last year in Australia. It will now commence the sale of its own branded products. Compass Clinics expects to inaugurate additional clinics in 2020. It offers consultation services for the patients, who want to get medical cannabis products via SAS (Special Access Scheme) or Authorized Prescriber pathways, in Australia. The company also uses the services of third-parties to sell cannabis oil and cannabis products.

Complies with minimum requirements to import cannabis

Chief Executive Officer of Medipharm Labs, Pat McCutcheon, said the company is excited to work with leading players like Compass Clinics to provide high-quality cannabis products to medical patients in Australia. The partnership with Cannabis Clinics helps the company to comply with the minimum requirements set by the Australian Government to import cannabis products.

Recently received import licenses, and Australian GMP certification helps the company to increase demand for its Pharma quality products. It also helps to expand its presence in the emerging worldwide markets and Australia.

Distribution of cannabis oil products in Australia

Medipharm Labs Australia will commence the supply of white-labeled cannabis oil under the trademark of Compass Clinics. The company will start receiving the formulated cannabis oil products from the Canadian TGA GMP certified facility of Medipharm Labs. It will distribute imported cannabis oil products to Compass Clinics in Australia.

President of Compass Clinics, David Martyn, said the company is pleased to offer GMP certified best-in-class, and pharmaceutical grade gel caps and cannabis oils to the growing patient base in Australia. He said Compass Clinics will benefit from its association with a leading producer of cannabis products – Medipharm Labs in serving its prevailing patient base. It also helps to expand its footprint in the surging medical cannabis space worldwide.

New scheduling status for CBD

The Australian authorities expect to consider a new scheduling status for cannabidiol. It expects to ensure the availability of CBD in low dosages early this year. The TGA is currently reviewing the safety of lower dosages of CBD.

Continue Reading

FEATURED STORIES

Business3 days ago

Acreage Holdings Inc (OTCMKTS:ACRGF) Inaugurates A Medical Dispensary – The Botanist In Spring Hill, Florida: Larissa Herda Resigns From The Board of Acreage

Post Views: 402 Acreage Holdings Inc (OTCMKTS:ACRGF) inaugurated The Botanist in the Spring Hill, Florida. It is the first medical...

Business4 days ago

TerrAscend Canada Inc, A Subsidiary Of Terrascend Corp (OTCMKTS:TRSSF), Enters A $80.5 Million CAD Loan Financing Accord With Canopy Growth Corp (NYSE:CGC)

Post Views: 432 TerrAscend Canada Inc, a subsidiary of Canopy Rivers Inc (OTCMKTS:CNPOF), has entered into an $80.5 Million CAD...

Business5 days ago

Medipharm Labs Corp (OTCMKTS:MEDIF) Expects To Begin Supply Of Pharmaceutical-quality cannabis oil products in Australia

Post Views: 489 Medipharm Labs Corp (OTCMKTS:MEDIF) will supply pharmaceutical quality cannabis oil products in Australia. It is on the...

Business6 days ago

Kannalife Inc (OTCMKTS:KLFE) Announces Receipt Of Australian Patent To Treat Hepatic Encephalopathy

Post Views: 370 Kannalife Inc (OTCMKTS:KLFE), a portfolio company of Medical Marijuana Inc (OTCMKTS:MJNA), has received an Australian patent No....

Business7 days ago

SinglePoint, Inc. (OTCMKTS:SING) Unveils Hemp Seed Oil Infused Hand Sanitizer – Klen Hands To Combat Coronavirus

Post Views: 462 SinglePoint, Inc. (OTCMKTS:SING) has unveiled hemp seed oil infused hand sanitizer – Klen Hands to help people...

Business1 week ago

CV Sciences Inc (OTCMKTS:CVSI) Reports Revenues Of $53.7 Million In 2019: Increases Retail Distribution Footprint To Over 5,500 Stores

Post Views: 712 CV Sciences Inc (OTCMKTS:CVSI) has reported revenues of $53.7 million (up 11%) in 2019. It also increased...

Whats Hot